Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Head & Neck 1Gynecologic 1

Conditions

Lymphoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × ASTX-660 × Clear all
NCT02503423 2026-03-20

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
253 enrolled
GynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Lymphoma

NCT04362007 2026-02-25

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Otsuka Pharmaceutical Co., Ltd.

Phase 1/2 Terminated
8 enrolled 11 charts
Lymphoid

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡